Additional European Equity News

AstraZeneca (AZN LN) - Q1 2026 (USD): Revenue 15.3bln (exp. 14.9bln), adj. EPS 2.58 (exp. 2.55). Confirms guidance for FY26. "...remain on track to achieve our ambition for 2030 and beyond." 2026 Guidance (reconfirmed) Total Revenue is expected to increase by a mid-to-high single-digit percentage Core EPS is expected to increase by a low double-digit percentage. (AstraZeneca) GSK (GSK LN) - Q1 2026 (GBP) Adj. EPS 46.5p (exp. 43.2p), Turnover 7.63bln (prev. 7.51bln Y/Y), Gross Profit 1.87bln (prev. 1.93bln Y/Y); reaffirms 2026 guidance Others: Speciality Medicines 3.2bln, Vaccines 2.1bln. Specialty Medicines +14% Y/Y; Respiratory, Immunology & Inflammation 0.9bln (+16%), Oncology 0.5bln (+28%), HIV 1.8bln (+10%). Vaccines +4% Y/Y; Shingrix 1.0bln (+20%), Meningitis vaccines 0.3bln (-3%), Arexvy 0.1bln (-18%). Dividend: Q1 2026 dividend of 17p declared; 70p expected for full year 2026. GBP 1.7bln executed to date as part of the GBP 2bln share buyback programme announced at FY2024. Guidance: Expect 2026 turnover growth of between 3% to 5%; Core operating profit growth of between 7% to 9%; Core EPS growth of between 7% to 9%. 2031 sales outlook of more than GBP 40bln. (GSK)Lloyds (LLOY LN) - Q1 2026 (GBP): Statutory Pretax Profit 2.03bln (exp. 1.78bln), NII 3.56bln (prev. 3.29bln Y/Y), EPS 2.4p (prev. 1.7p Y/Y); reiterated guidance Guidance: "We are confident in our delivery for the year ahead and reiterate our guidance for 2026. We look forward to presenting our new strategy alongside the half-year results". Impairment: The underlying impairment charge was GBP 295mln (prev. GBP 309mln Y/Y), resulting in an asset quality ratio of 25 basis points. The MES charge reflects a £151 million impact from the deterioration in economic outlook as a result of the Middle East conflict. (Lloyds) TotalEnergies (TTE FP) - Q1 2026 (USD): adj. Net 5.39bln (exp. 4.98bln), Cash Flow 8.6bln (prev. 7.2bln Q/Q), Net income 5.8bln (prev. 2.9bln Q/Q), adj. EBITDA 12.6bln (prev. 10.1bln Q/Q). To continue buybacks. Outlook: Given the time required to restart production facilities in the Middle East (2-3 months), prices should remain at high levels during the second quarter. Competition between LNG demand in Europe to replenish storage and in Asia for the warm season should support prices in the coming months. (TotalEnergies)